Pérez CMC

Language: Spanish
References: 23
Page: 95-98
PDF size: 129.69 Kb.

REFERENCES

1. Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S. Italian consensus on treatment of spasticity in multiple sclerosis. Eur J Neurol. 2020; 27: 445-453. doi: 10.1111/ene.14110.

2. Bahr LS, Bock M, Liebscher D, Bellmann-Strobl J, Franz L, Prüb A, et al. Ketogenic diet and fasting diet as nutritional approaches in multiple sclerosis (NAMS): protocol of a randomized controlled study. Trials. 2020; 21(1): 1-9.

3. Beitollahi M, Forouzi MA, Tirgari B, Jahani Y. Fatigue, stigma, and mood in patients with multiple sclerosis: effectiveness of guided imagery. BMC Neurol [Internet]. 2022; 22(1): 1-9. Available in: https://doi.org/10.1186/s12883-022-02677-3

4. Broch L, Flemmen HO, Simonsen CS, Berg-Hansen P, Ormstad H, Brunborg C, Celius EG. Fatigue in multiple sclerosis is associated with socioeconomic factors. Mult Scler Relat Disord. 2022; 64: 103955.

5. Cortés-Pérez I, Sánchez-Alcalá M, Nieto-Escámez FA, Castellote-Caballero Y, Obrero-Gaitán E, Osuna-Pérez MC. Virtual reality-based therapy improves fatigue, impact, and quality of life in patients with M. sclerosis. A systematic review with a meta-analysis. Sensors (Basel). 2021; 21(21): 7389.

6. Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021; 20(1): 38-48.

7. Harrison AM, Safari R, Mercer T, Picariello F, Van der Linden ML, White C, et al. Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis. Mult Scler J. 2021; 27(11): 1657-1678.

8. Heitmann H, Andlauer TFM, Korn T, Muhlau M, Henningsen P, Hemmer B, et al. Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms. Mult Scler J. 2022; 28(7): 1020-1027.

9. Palotai M, Nazeri A, Cavallari M, Healy BC, Glanz B, Gold SM, et al. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019; 9(1): 14781.

10. Herden L, Weissert R. The effect of coffee and caffeine consumption on patients with multiple sclerosis-related fatigue. Nutrients. 2020; 12(8): 2262.

11. Hubbard AL, Golla H, Lausberg H. What's in a name? That which we call multiple sclerosis fatigue. Mult Scler J. 2021; 27(7): 983-938.

12. Zhang T, Yan HX, An Y, Yin L, Sun PP, Zhao JN, et al. The efficacy and safety of manual therapy for symptoms associated with multiple sclerosis: a systematic review and meta-analysis. J Integr Complement Med. 2022; 28(10): 780-790.

13. Neuhaus O, Köhler W, Then Bergh F, Kristoferitsch W, Faiss J, Rosenkranz T, et al. Glatiramer acetate treatment in multiple sclerosis-associated fatigue-beneficial effects on self-assessment scales but not on molecular markers. Biomolecules. 2021; 11(3): 393.

14. Amatya B, Young J, Khan F. Non-pharmacological interventions for chronic pain in multiple sclerosis. Cochrane Database Syst Rev. 2018; 12(12): CD012622.

15. Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain. 2019; 20(1): 20.

16. Oliveira RAA, Baptista AF, Sá KN, Barbosa LM, Nascimento OJMD, Listik C, et al. Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology. Arq Neuropsiquiatr. 2020; 78(11): 741-752. Available in: https://pubmed.ncbi.nlm.nih.gov/33331468/

17. Rivel M, Achiron A, Dolev M, Stern Y, Zeilig G, Defrin R. Unique features of central neuropathic pain in multiple sclerosis: results of a cluster analysis. Eur J Pain. 2022; 26(5): 1107-1122.

18. Kratz AL, Whibley D, Alschuler KN, Ehde DM, Williams DA, Clauw DJ, Braley TJ. Characterizing chronic pain phenotypes in multiple sclerosis: a nationwide survey study. Pain. 2021; 162(5): 1426-1433.

19. Al Dehailan AS. Paroxysmal dystonia as an initial presentation of multiple sclerosis posing a diagnostic challenge. Neurosciences. 2019; 24(3): 236-239.

20. Ghosh R, Roy D, Dubey S, Das S, Benito-León J. Movement disorders in multiple sclerosis: an update. Tremor Other Hyperkinet Mov (N Y). 2022; 12: 14.

21. Artusi CA, Farooqi A, Romagnolo A, Marsili L, Balestrino R, Sokol LL, et al. Deep brain stimulation in uncommon tremer disorders: indications, targets, and programming. J Neurol. 2018; 265(11): 2473-2493.

22. Western DG, Neild SA, Jones R, Davies-Smith A. Personalised profiling to identify clinically relevant changes in tremor due to multiple sclerosis. BMC Med Inform Decis Mak. 2019; 19(1): 162.

23. Puschmann A, Wszolek ZK. Diagnosis and treatment of common forms of tremor. Semin Neurol. 2011; 31(1): 65-77.